In contrast to NewLink Genetics, Northwest Biotherapeutics' interim analysis was a boon to the company's investors, as word that its Phase III trial of a personalized cancer vaccine was going according to plan sent its shares up as much as 10%.
After an interim analysis, NewLink Genetics is planning to keep on keeping on with a Phase III study of its cancer vaccine. But that news came as an apparent disappointment to investors, who hoped the drug's promise would result in an early trial termination, and the biotech's shares fell more than 12% on Friday morning.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
NewLink Genetics presented updates on its cancer vaccines, HyperAcute Pancreas (algenpantucel-L) and HyperAcute Lung (tergenpumatucel-L), at the American Society of Clinical Oncology 2012 Annual Meeting.
Pancreatic cancer is hard to treat, but adding a cancer vaccine to standard chemotherapy could boost survival.
The Scientist takes a crack at covering the few courageous--or is it foolhardy?--biotech companies willing to go public these days. Steven Burrill notes that there's no appetite for risk, echoing...
It's worth letting out a "hooray" when a biotech does an initial public offering. NewLink Genetics, a cancer vaccine developer, made its public debut today, raising about $43.4 million through the
An Iowa-based biotech named NewLink Genetics is gambling that its late-stage therapeutic cancer vaccine can light a fire under investors as it sets out to garner up to $66 million from an IPO.
NewLink Genetics in Ames, Iowa, has grabbed $7.5 million in a Series D financing designed to accelerate the clinical development of its therapeutic cancer products. The financing involved additional